LIGAND PHARMACEUTICALS INC Insider Trading for February 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for February 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 2014 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Sell | S | 72.25 | 500 | 36,125 | 20,546 | 21 K to 20.5 K (-2.38 %) |
| Feb 21 2014 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 72.97 | 900 | 65,676 | 1,843 | 2.7 K to 1.8 K (-32.81 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.05 | 5,359 | 391,464 | 79,390 | 84.7 K to 79.4 K (-6.32 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.05 | 112,369 | 8,208,319 | 1,685,344 | 1.8 M to 1.7 M (-6.25 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.05 | 10,557 | 771,167 | 158,684 | 169.2 K to 158.7 K (-6.24 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.05 | 18,615 | 1,359,787 | 279,842 | 298.5 K to 279.8 K (-6.24 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.03 | 2,771 | 202,375 | 84,749 | 87.5 K to 84.7 K (-3.17 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.03 | 57,370 | 4,189,920 | 1,797,713 | 1.9 M to 1.8 M (-3.09 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.03 | 5,395 | 394,015 | 169,241 | 174.6 K to 169.2 K (-3.09 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 73.03 | 9,464 | 691,187 | 298,457 | 307.9 K to 298.5 K (-3.07 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 74.66 | 14,003 | 1,045,409 | 87,520 | 101.5 K to 87.5 K (-13.79 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 74.66 | 153,751 | 11,478,450 | 1,855,083 | 2 M to 1.9 M (-7.65 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 74.66 | 16,331 | 1,219,209 | 174,636 | 191 K to 174.6 K (-8.55 %) |
| Feb 20 2014 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 74.66 | 16,915 | 1,262,808 | 307,921 | 324.8 K to 307.9 K (-5.21 %) |
| Feb 19 2014 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 73.31 | 3,900 | 285,919 | 40,796 | 44.7 K to 40.8 K (-8.73 %) |
| Feb 19 2014 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 73.31 | 11,531 | 845,368 | 233,361 | 244.9 K to 233.4 K (-4.71 %) |
| Feb 19 2014 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 77.10 | 6,700 | 516,583 | 44,696 | 51.4 K to 44.7 K (-13.04 %) |
| Feb 19 2014 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 77.10 | 19,769 | 1,524,229 | 244,892 | 264.7 K to 244.9 K (-7.47 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 78.87 | 9,500 | 749,265 | 244,716 | 254.2 K to 244.7 K (-3.74 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 77.43 | 6,700 | 518,779 | 254,216 | 260.9 K to 254.2 K (-2.57 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 75.21 | 24,120 | 1,814,121 | 260,916 | 285 K to 260.9 K (-8.46 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 21.92 | 4,584 | 100,481 | 10,984 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 21.00 | 1,166 | 24,486 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 16.14 | 1,000 | 16,140 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 14.47 | 14,622 | 211,580 | 8,582 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 10.05 | 6,086 | 61,164 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 9.96 | 7,495 | 74,650 | 347 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 40.86 | 8,333 | 340,486 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 21.00 | 6,012 | 126,252 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 21.00 | 7,321 | 153,741 | 6,012 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 16.14 | 16,666 | 268,989 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 14.47 | 2,879 | 41,659 | 8,917 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | M | 10.05 | 10,789 | 108,429 | 13,125 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 7,495 | 556,654 | 17,667 | 25.2 K to 17.7 K (-29.79 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 9.96 | 7,495 | 74,650 | 25,162 | 17.7 K to 25.2 K (+42.42 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 4,584 | 340,454 | 17,667 | 22.3 K to 17.7 K (-20.60 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 21.92 | 4,584 | 100,481 | 22,251 | 17.7 K to 22.3 K (+25.95 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 14,622 | 1,085,976 | 17,667 | 32.3 K to 17.7 K (-45.28 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 14.47 | 14,622 | 211,580 | 32,289 | 17.7 K to 32.3 K (+82.76 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 75.73 | 2,879 | 218,027 | 17,667 | 20.5 K to 17.7 K (-14.01 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 14.47 | 2,879 | 41,659 | 20,546 | 17.7 K to 20.5 K (+16.30 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 75.73 | 10,789 | 817,051 | 17,667 | 28.5 K to 17.7 K (-37.91 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 10.05 | 10,789 | 108,429 | 28,456 | 17.7 K to 28.5 K (+61.07 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 6,086 | 452,007 | 17,667 | 23.8 K to 17.7 K (-25.62 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 10.05 | 6,086 | 61,164 | 23,753 | 17.7 K to 23.8 K (+34.45 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 75.73 | 6,012 | 455,289 | 17,667 | 23.7 K to 17.7 K (-25.39 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 21.00 | 6,012 | 126,252 | 23,679 | 17.7 K to 23.7 K (+34.03 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 7,321 | 543,731 | 17,667 | 25 K to 17.7 K (-29.30 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 21.00 | 7,321 | 153,741 | 24,988 | 17.7 K to 25 K (+41.44 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 75.73 | 8,333 | 631,058 | 17,667 | 26 K to 17.7 K (-32.05 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 40.86 | 8,333 | 340,486 | 26,000 | 17.7 K to 26 K (+47.17 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 1,000 | 74,270 | 17,667 | 18.7 K to 17.7 K (-5.36 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 16.14 | 1,000 | 16,140 | 18,667 | 17.7 K to 18.7 K (+5.66 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 16,666 | 1,237,784 | 17,667 | 34.3 K to 17.7 K (-48.54 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 16.14 | 16,666 | 268,989 | 34,333 | 17.7 K to 34.3 K (+94.33 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Sell | S | 74.27 | 1,166 | 86,599 | 17,667 | 18.8 K to 17.7 K (-6.19 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Buy | M | 21.00 | 1,166 | 24,486 | 18,833 | 17.7 K to 18.8 K (+6.60 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 21.92 | 4,584 | 100,481 | 10,560 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 21.00 | 1,166 | 24,486 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 16.14 | 1,000 | 16,140 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 10.05 | 4,779 | 48,029 | 0 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 9.96 | 1,736 | 17,291 | 347 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 14.47 | 2,000 | 28,940 | 13,130 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 74.42 | 20,000 | 1,488,400 | 20,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 42.90 | 386 | 16,559 | 4,947 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 14.47 | 1,230 | 17,798 | 1,620 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 14.47 | 2,000 | 28,940 | 31,645 | 29.6 K to 31.6 K (+6.75 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 9.96 | 1,736 | 17,291 | 29,645 | 27.9 K to 29.6 K (+6.22 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 1,736 | 129,332 | 27,909 | 29.6 K to 27.9 K (-5.86 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 1,230 | 91,635 | 29,645 | 30.9 K to 29.6 K (-3.98 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 14.47 | 1,230 | 17,798 | 30,875 | 29.6 K to 30.9 K (+4.15 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 4,779 | 356,036 | 29,645 | 34.4 K to 29.6 K (-13.88 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 10.05 | 4,779 | 48,029 | 34,424 | 29.6 K to 34.4 K (+16.12 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 4,584 | 341,508 | 29,645 | 34.2 K to 29.6 K (-13.39 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 21.92 | 4,584 | 100,481 | 34,229 | 29.6 K to 34.2 K (+15.46 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 1,000 | 74,500 | 29,645 | 30.6 K to 29.6 K (-3.26 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 16.14 | 1,000 | 16,140 | 30,645 | 29.6 K to 30.6 K (+3.37 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 1,166 | 86,867 | 29,645 | 30.8 K to 29.6 K (-3.78 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 21.00 | 1,166 | 24,486 | 30,811 | 29.6 K to 30.8 K (+3.93 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.50 | 386 | 28,757 | 29,645 | 30 K to 29.6 K (-1.29 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 42.90 | 386 | 16,559 | 30,031 | 29.6 K to 30 K (+1.30 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 2,500 | 0 | 29,645 | 27.1 K to 29.6 K (+9.21 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | M | 9.96 | 16,875 | 168,075 | 48,125 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 74.42 | 10,000 | 744,200 | 95,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 74.42 | 10,000 | 744,200 | 85,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 74.42 | 75,000 | 5,581,500 | 75,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Grant | A | 0.00 | 8,000 | 0 | 119,099 | 111.1 K to 119.1 K (+7.20 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Sell | S | 75.00 | 16,875 | 1,265,625 | 111,099 | 128 K to 111.1 K (-13.19 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Buy | M | 9.96 | 16,875 | 168,075 | 127,974 | 111.1 K to 128 K (+15.19 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | A | 74.42 | 10,000 | 744,200 | 65,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | A | 74.42 | 10,000 | 744,200 | 55,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | A | 74.42 | 45,000 | 3,348,900 | 45,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | M | 9.97 | 22,500 | 224,325 | 133,056 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | M | 9.97 | 3,444 | 34,337 | 155,556 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Sell | S | 79.54 | 22,500 | 1,789,650 | 53,457 | 76 K to 53.5 K (-29.62 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Buy | M | 9.97 | 22,500 | 224,325 | 75,957 | 53.5 K to 76 K (+42.09 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Buy | M | 9.97 | 3,444 | 34,337 | 53,457 | 50 K to 53.5 K (+6.89 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Grant | A | 0.00 | 5,000 | 0 | 50,013 | 45 K to 50 K (+11.11 %) |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Option Exercise | A | 74.42 | 5,000 | 372,100 | 45,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Option Exercise | A | 74.42 | 5,000 | 372,100 | 40,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Option Exercise | A | 74.42 | 35,000 | 2,604,700 | 35,000 | |
| Feb 14 2014 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Grant | A | 0.00 | 3,000 | 0 | 18,659 | 15.7 K to 18.7 K (+19.16 %) |